{"pmid":32405226,"pmcid":"PMC7217791","title":"Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","text":["Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties.","Pharmacol Res","Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai","32405226"],"abstract":["Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties."],"journal":"Pharmacol Res","authors":["Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405226","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104901","keywords":["2dg, 2-deoxy-d-glucose","3-nt, 3-nitrotyrosine","4ebp1, eukaryotic translation initiation factor 4e-binding protein 1","8-ohdg, 8-hydroxy-2'-deoxyguanosine","8-iso, 8-isoprostane","abcg2, atp-binding cassette subfamily member 2","ace2, angiotensin-converting enzyme 2","aec, alveolar epithelial cells","ahr, airway hyperresponsiveness","aif, apoptosis-inducing factor","ali, acute lung injury","ap-1, activator protein 1","artd, artemisinin-daumone hybrid 15","asc, apoptosis-associated speck-like protein containing card","atf3, activating transcription factor 3","atp, adenosine triphosphate","arteether (pubchem cid: 3000469)","artemether (pubchem cid: 68911)","artemisitene (pubchem cid: 11000442)","artesunate (pubchem cid:156252)","axin2, axis inhibition protein 2","balf, bronchoalveolar lavage fluid","bdha, biotinylated dihydroartesunate","cddp, cisplatin","cdk, cyclin-dependent kinase","copd, chronic obstructive pulmonary disease","covid-19","cox-2, cyclooxygenase-2","cse, cigarette smoke extract","ctx, cyclophosphamide","chemical compounds studied in this article artemisinin (pubchem cid: 68827)","dha, dihydroartemisinin","dha-nlc, dihydroartemisinin-nanostructured lipid carriers","dlaedried, leaf artemisia extract","dna, deoxyribonucleic acid","dihydroartemisinin (pubchem cid: 139073990)","e2f1, e2f transcription factor 1","egfr, epidermal growth factor receptor","emt, epithelial-mesenchymal transition","er, endoplasmic reticulum","foxo1, forkhead box o1","glut, glucose transporter","gpx, glutathione peroxidase","gsh, glutathione","gsk3beta, glycogen synthase kinase 3 beta","h2ax, h2a histone family member x","hcmv, human cytomegalovirus","hdac2, histone deacetylase 2","helf, human embryonic lung fibroblasts","hif-1alpha, hypoxia-inducible factor 1-alpha","hnf4a, hepatocyte nuclear factor 4 alpha","ho-1, heme oxygenase-1","icam-1, intercellular adhesion molecule 1","il, interleukin","inf, interferon","ip-10, ifngamma-induced protein 10","ikappabalpha, inhibitor of nf-kappab alpha","jnk, c-jun n-terminal kinase","kc, keratinocyte chemoattractant","kdr/flk-1, kinase insert domain receptor /fetal liver kinase-1","keap1, kelch-like ech-associated protein 1","ladpi, liposomal artesunate dry powder inhalers","ld50, lethal dose","llc, lewis lung carcinoma","lmvd, lymphatic microvessel density","lps, lipopolysaccharide","lymp, lymphocyte","mapk, mitogen-activated protein kinases","mcp-1, monocyte chemoattractant protein-1","mda, malondialdehyde","mip-2, macrophage inflammatory protein 2","mmp, matrix metalloproteinase","mpo, myeloperoxidase","mac, macrophage","mcl-1, myeloid cell leukemia-1","nf-kappab, nuclear factor-kappa b","nkd2, naked cuticle homolog 2","nlrp3, nlr family pyrin domain containing 3","no, nitric oxide","nox, nadph oxidase","npc, nasopharyngeal carcinoma","nqo1, nad(p)h quinone dehydrogenase 1","nsclc, non-small cell lung cancer","nrf2, nuclear factor erythroid 2-related factor 2","ova, ovalbumin","pcna, proliferating cell nuclear antigen","peg, polyethylene glycol","pge2, prostaglandin e2","pi3k, phosphoinositide 3-kinase","ra, fls rheumatoid arthritis fibroblast-like synoviocytes","rankl, receptor activator of nuclear factor kappa-b ligand","rir, renal ischemia reperfusion","rnai, rna interference","ros, reactive oxygen species","rb, retinoblastoma","respiratory diseases","sclc, small cell lung cancer","sle, systemic lupus erythematosus","sod, superoxide dismutase","stat, signal transducers and activators of transcription","smac, second mitochondrial activator of caspases","tgf, tumour growth factor","timp, tissue inhibitor of metalloproteinases","tlr4, toll-like receptor 4","tnf, tumour necrosis factor","tslp, thymic stromal lymphopoietin","th17, t helper 17","treg, regulatory t","vcam-1, vascular cell adhesion molecule 1","vdac2, voltage-dependent anion channel 2","vegf, vascular endothelial growth factor","xiap, x-linked inhibitor of apoptosis protein","ykl-40, chitinase-like glycoprotein","ym2, chitinase 3-like protein 4","[ca2+]i, intracellular calcium ion","artemisinin","cell proliferation","eos, eosinophil","hsp47, heat shock protein 47","inos, inducible nitric oxide synthase","inflammation","lung","mtor, mammalian target of rapamycin","neu, neutrophil","shrna, short hairpin rna","sm-alpha, actin smooth muscle-alpha actin","u-pa, urokinase-type plasminogen activator"],"e_drugs":["artemisinine","Reactive Oxygen Species","Peroxides","Artemisinins"],"topics":["Treatment"],"weight":1,"_version_":1666802845647634432,"score":9.490897,"similar":[{"pmid":32475812,"title":"Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","text":["Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making it effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties.","Pharmacol Res","Cheong, Dorothy H J","Tan, Daniel W S","Wong, Fred W S","Tran, Thai","32475812"],"abstract":["Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making it effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties."],"journal":"Pharmacol Res","authors":["Cheong, Dorothy H J","Tan, Daniel W S","Wong, Fred W S","Tran, Thai"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475812","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.phrs.2020.104901","keywords":["arteether (pubchem cid: 3000469)","artemether (pubchem cid: 68911)","artemisinin","artemisitene (pubchem cid: 11000442)","artesunate (pubchem cid:156252)","covid-19","cell proliferation","chemical compounds studied in this article artemisinin (pubchem cid: 68827)","dihydroartemisinin (pubchem cid: 139073990)","inflammation","lung","respiratory diseases"],"topics":["Treatment"],"weight":1,"_version_":1668437835209768960,"score":1172.6729},{"pmid":32267139,"title":"Hsa-miR-217 Inhibits the Proliferation, Migration and Invasion in Non-small-cell Lung Cancer Cells Via Targeting SIRT1 and p53/KAI1 Signaling","text":["Hsa-miR-217 Inhibits the Proliferation, Migration and Invasion in Non-small-cell Lung Cancer Cells Via Targeting SIRT1 and p53/KAI1 Signaling","Background: Brain metastasis is a major cause for cancer death in patients with lung cancer. Sirtuin 1 (SIRT1) and hsa-miR-217 has been identified to mediate the development of non-small cell lung cancer (NSCLC). Aims: We performed this study to investigate the roles of hsa-miR-217, its target SIRT1, as well as P53/KAI1 axis in the brain metastasis from NSCLC. Study design: This is a cell culture study. Methods: Human pulmonary adenocarcinoma brain metastasis cell line PC-14/B were incubated and treated with constructed lentiviral plasmids expressing miR-217 and/or SIRT1. BEAS-2B cell line was used as a control. The targeted regulation of miR-217 to SIRT1 was examined using dual luciferase reporter assay. Cell proliferation, migration, invasion and the expression of relate proteins were detected to examine the effect of miR-217/SIRT1 expression on metastasis. Results: PC-14/B cells expressed higher SIRT1 and lower p53 and KAI1 compared with BEAS-2B control cells (P<0.05). SIRT1 was a direct target of miR-217. MiR-217 expression suppressed PC-14/B cell invasion (P=0.004), migration (P=0.001) and proliferation (P<0.05), whereas SIRT1 overexpression reversed all processes. SIRT1 expression inhibited P53, KAI1/CD82, matrix metalloproteinase (MMP)-9 and beta-catenin but upregulated E-cadherin protein. MiR-217 overexpression induced reverse changes. Conclusions: Hsa-miR-217 and its target SIRT1 acted as metastasis suppressor and promoter gene in NSCLC, respectively. The hsa-miR-217/SIRT1/P53/KAI1 metastasis regulatory pathway showed novel and crucial roles in brain metastasis from NSCLC. This axis might be a potential target for the treatment of brain metastasis of lung cancer.","Balkan Med J","Jiang, Wenxia","Hou, Likun","Wei, Juan","Du, Yifeng","Zhao, Yan","Deng, Xue","Lin, Xiangdong","32267139"],"abstract":["Background: Brain metastasis is a major cause for cancer death in patients with lung cancer. Sirtuin 1 (SIRT1) and hsa-miR-217 has been identified to mediate the development of non-small cell lung cancer (NSCLC). Aims: We performed this study to investigate the roles of hsa-miR-217, its target SIRT1, as well as P53/KAI1 axis in the brain metastasis from NSCLC. Study design: This is a cell culture study. Methods: Human pulmonary adenocarcinoma brain metastasis cell line PC-14/B were incubated and treated with constructed lentiviral plasmids expressing miR-217 and/or SIRT1. BEAS-2B cell line was used as a control. The targeted regulation of miR-217 to SIRT1 was examined using dual luciferase reporter assay. Cell proliferation, migration, invasion and the expression of relate proteins were detected to examine the effect of miR-217/SIRT1 expression on metastasis. Results: PC-14/B cells expressed higher SIRT1 and lower p53 and KAI1 compared with BEAS-2B control cells (P<0.05). SIRT1 was a direct target of miR-217. MiR-217 expression suppressed PC-14/B cell invasion (P=0.004), migration (P=0.001) and proliferation (P<0.05), whereas SIRT1 overexpression reversed all processes. SIRT1 expression inhibited P53, KAI1/CD82, matrix metalloproteinase (MMP)-9 and beta-catenin but upregulated E-cadherin protein. MiR-217 overexpression induced reverse changes. Conclusions: Hsa-miR-217 and its target SIRT1 acted as metastasis suppressor and promoter gene in NSCLC, respectively. The hsa-miR-217/SIRT1/P53/KAI1 metastasis regulatory pathway showed novel and crucial roles in brain metastasis from NSCLC. This axis might be a potential target for the treatment of brain metastasis of lung cancer."],"journal":"Balkan Med J","authors":["Jiang, Wenxia","Hou, Likun","Wei, Juan","Du, Yifeng","Zhao, Yan","Deng, Xue","Lin, Xiangdong"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267139","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.4274/balkanmedj.galenos.2020.2019.9.91","keywords":["brain metastasis","hsa-mirna-217","lung cancer","pc-14/b cells","sirtuin 1"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491880210434,"score":120.179214},{"pmid":32271454,"title":"Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.","text":["Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.","Beginning in December 2019, coronavirus disease 2019 (COVID-19), due to 2019-nCoV infection, emerged in Wuhan and spread rapidly throughout China and even worldwide. Employing combined therapy of modern medicine and traditional Chinese medicine has been proposed, in which Ma Xing Shi Gan Decoction (MXSGD) was recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. We investigated the underlying mechanism of MXSGD in treating COVID-19 utilizing the approaches of integrating network pharmacology. A total of 97 active ingredients of MXSGD were screened out, and 169 targets were predicted. The protein-protein interaction network exhibited hub targets of MXSGD, such as Heat shock protein 90, RAC-alpha serine/threonine-protein kinase, Transcription factor AP-1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Vascular endothelial growth factor A, and Tumour necrosis factor. Gene Ontology functional enrichment analysis demonstrated that the biological processes altered within the body after taking MXSGD were closely related to the regulation of such processes as the acute inflammatory response, chemokine production, vascular permeability, response to oxygen radicals, oxidative stress-induced apoptosis, T cell differentiation involved in the immune response, immunoglobulin secretion, and extracellular matrix disassembly. KEGG enrichment analysis indicated that the targets of MXSGD were significantly enriched in inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. The therapeutic mechanisms of MXSGD on COVID-19 may primarily involve the following effects: reducing inflammation, suppressing cytokine storm, protecting the pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating the immune response, and decreasing fever.","Eur Rev Med Pharmacol Sci","Wang, Y-X","Ma, J-R","Wang, S-Q","Zeng, Y-Q","Zhou, C-Y","Ru, Y-H","Zhang, L","Lu, Z-G","Wu, M-H","Li, H","32271454"],"abstract":["Beginning in December 2019, coronavirus disease 2019 (COVID-19), due to 2019-nCoV infection, emerged in Wuhan and spread rapidly throughout China and even worldwide. Employing combined therapy of modern medicine and traditional Chinese medicine has been proposed, in which Ma Xing Shi Gan Decoction (MXSGD) was recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. We investigated the underlying mechanism of MXSGD in treating COVID-19 utilizing the approaches of integrating network pharmacology. A total of 97 active ingredients of MXSGD were screened out, and 169 targets were predicted. The protein-protein interaction network exhibited hub targets of MXSGD, such as Heat shock protein 90, RAC-alpha serine/threonine-protein kinase, Transcription factor AP-1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Vascular endothelial growth factor A, and Tumour necrosis factor. Gene Ontology functional enrichment analysis demonstrated that the biological processes altered within the body after taking MXSGD were closely related to the regulation of such processes as the acute inflammatory response, chemokine production, vascular permeability, response to oxygen radicals, oxidative stress-induced apoptosis, T cell differentiation involved in the immune response, immunoglobulin secretion, and extracellular matrix disassembly. KEGG enrichment analysis indicated that the targets of MXSGD were significantly enriched in inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. The therapeutic mechanisms of MXSGD on COVID-19 may primarily involve the following effects: reducing inflammation, suppressing cytokine storm, protecting the pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating the immune response, and decreasing fever."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Wang, Y-X","Ma, J-R","Wang, S-Q","Zeng, Y-Q","Zhou, C-Y","Ru, Y-H","Zhang, L","Lu, Z-G","Wu, M-H","Li, H"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271454","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20704","locations":["Wuhan","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491843510272,"score":116.50685},{"pmid":32405269,"pmcid":"PMC7217787","title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","text":["Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","Clin Immunol","Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume","32405269"],"journal":"Clin Immunol","authors":["Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405269","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.clim.2020.108464","keywords":["cd, cluster of differentiation","covid-19, corona-virus-disease-2019","ctla-4, cytotoxic t lymphocyte associated protein 4","g-csf, granulocyte colony stimulating factor","ifn-gamma, interferon gamma","il, interleukin","ip-10, interferon gamma-induced protein 10","mcp-1, monocyte chemoattractant protein 1","mip-1alpha, macrophage inflammatory protein 1 alpha","nf-kappab, nuclear factor-kappa b","nlrp3, nucleotide-binding oligomerization domain (nod)-like receptor family, pyrin domain containing 3","pd-1, programmed cell death 1","ros, reactive oxygen species","sars-cov-2, severe acute respiratory syndrome coronavirus 2","tigit, t-cell immunoreceptor with ig and itim (immunoreceptor tyrosine-based inhibition motif) domains","tlr, toll like receptor","tnfalpha, tumor necrosis factor alpha","tim-3, t-cell immunoglobulin mucin-3","mtor, mammalian target of rapamycin"],"e_drugs":["Sirolimus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845466230785,"score":116.226326},{"pmid":32413619,"title":"beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","text":["beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm.","Sci Total Environ","Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J","32413619"],"abstract":["Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm."],"journal":"Sci Total Environ","authors":["Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413619","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.scitotenv.2020.139330","keywords":["covid-19","cytokine storm","disease mitigation","immunomodulation","medicinal mushroom","beta-glucans"],"locations":["Carbosynth-Lentinan","Lentinan","Lentinan","Lentinan","beta-Glucan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666897319252983808,"score":114.07174}]}